Isoxicam

Isoxicam
Clinical data
Trade names	Maxicam
ATC code	M01AC03 (WHO) (withdrawn);
Identifiers
CAS Number	34552-84-6;
PubChem CID	54677972;
DrugBank	DB08942 ;
ChemSpider	10442695 ;
UNII	8XU734C4NG;
KEGG	D04639 ;
ChEBI	CHEBI:CHEBI:76163 ;
CompTox Dashboard (EPA)	DTXSID0045462 ;
ECHA InfoCard	100.047.334
Chemical and physical data
Formula	C14H13N3O5S
Molar mass	335.33 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=NO1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O;

Isoxicam is a nonsteroidal anti-inflammatory drug (NSAID) that was taken or applied to reduce inflammation and as an analgesic reducing pain in certain conditions. The drug was introduced in 1983 by the Warner-Lambert Company. Isoxicam is a chemical analog of piroxicam (Feldene) which has a pyridine ring in lieu of an isoxazole ring. In 1985 isoxicam was withdrawn from the French market, due to adverse effects, namely toxic epidermal necrolysis resulting in death. Although these serious side effects were observed only in France, the drug was withdrawn worldwide.^[1]^[2]

References

^ Consolidated List of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by Governments, United Nations, 2003, p. 123 link to 2005 ed
^ Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E (January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134. S2CID 73036562.

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

[1] Consolidated List of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by Governments, United Nations, 2003, p. 123 link to 2005 ed

[2] Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E (January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134. S2CID 73036562.

[1]

[2]